07630

8.1007.06%
SC

Sui-Xiong Cai

CEO & Executive Director

Dr. Sui-Xiong Cai is Chief Executive Officer of IMPACT Therapeutics, Inc. and has been its Executive Director since September 23, 2025. Dr. Cai was a Director of IMPACT Therapeutics, Inc from June 2014 to September 23, 2025. Dr. Cai was Chief Technology Officer of IMPACT Therapeutics, Inc. Dr. Cai worked at the University of Oregon from 1990 to 1993 after his doctoral degree, published over 20 papers and obtained six issued patents within the U.S. In 1994, he worked at ACEA Pharmaceuticals Inc., published four papers and obtained seven issued patents within the U.S. After CoCensys Inc. acquired ACEA Pharmaceuticals Inc. in May 1994, he worked at CoCensys Inc. until March 1998, published over 15 papers and obtained over 25 issued patents within the U.S. Since the spinoff of Cytovia Inc. from CoCensys Inc. in April 1998, Dr. Cai worked at Cytovia Inc. until May 2000, published one paper and obtained over 40 issued patents within the U.S. After the acquisition of Cytovia Inc. by Maxim Pharmaceuticals Limited in June 2000, Dr. Cai worked at Maxim Pharmaceuticals until December 2005, published 19 papers. After EpiCept Corporation completed the merger with Maxim Pharmaceuticals Limited in January 2006, Dr. Cai served as senior director of chemistry at EpiCept Corporation until 2009, published over 35 papers and obtained three issued patents within the U.S. Dr. Cai obtained his bachelor’s degree in chemistry from University of Science and Technology of China in 1983 and his doctoral degree in organic chemistry from University of Oregon in June 1990.

Positions